RxDoctor Payments Data

Nimmie Singh, DO

Family Medicine · San Francisco, CANPI 1255868055

Payments from drug & device makers

$1,366in general payments, 2019–2025

Across 15 payments — averaging $91.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$291
  • Gilead$221
  • Teva Pharmaceuticals USA, Inc.$213
  • Edwards Lifesciences$139
  • Merck$120
  • Amgen$104
  • plus $279 from 5 others

What the payments were for

  • Food & beverage$1,366100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,366 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$212,226
Medicare patients
711
Services billed
1,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$8,893
JardianceEmpagliflozin17$7,198
Lacosamide15$1,800
Atorvastatin Calcium111$1,414
Oxycodone Hcl69$952
Mirtazapine52$873
Gabapentin70$800
Pantoprazole Sodium97$728
Amlodipine Besylate74$728
Tamsulosin Hcl32$720
Metoprolol Succinate34$686
Metformin Hcl90$644
Albuterol Sulfate HfaAlbuterol Sulfate12$632
Nystatin25$552
Amiodarone Hcl12$525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$89$8,89330 claims
Boehringer IngelheimJardiance$85$7,19817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →